(Updated as of 14 March 2023) On 24 January 2023, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation for the government financing of recombinant Human Erythropoietin (epoetin alfa) 4000 IU/mL solution for injection (IV/SC), 1mL pre-filled syringe, for the management of chemotherapy-induced anemia in patients with non-myeloid disease through its minor inclusion continue reading : HTAC Guidance: PNF Inclusion of Recombinant Human Erythropoietin (Epoetin Alfa) 4000 IU/mL Solution for Injection (IV/SC) 1mL Pre-filled Syringe
HTAC Guidance: PNF Inclusion of Filgrastim 300 mcg/0.9 mL Solution (IV, SC), 0.9 mL Pre-filled Syringe
(Updated as of 14 March 2023) On 24 January 2023, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation for the government financing of Filgrastim 300 mcg/0.9 mL solution (IV, SC), 0.9 mL pre-filled syringe, for the treatment of neutropenia in patients undergoing bone marrow transplantation and patients receiving myelosuppressive cancer chemotherapy through continue reading : HTAC Guidance: PNF Inclusion of Filgrastim 300 mcg/0.9 mL Solution (IV, SC), 0.9 mL Pre-filled Syringe
[Announcement] Ceremonial Turnover of HTA Implementation from the Department of Health to the Department of Science and Technology
The Department of Health (DOH) officially transferred the operations of the Health Technology Assessment (HTA) Philippines to the Department of Science and Technology (DOST) through a ceremonial turnover of the HTA Council and HTA Division from the DOH to the DOST on 06 March 2023 at the Philippine International Convention Center (PICC), Manila. DOH Officer-in-Charge-Secretary continue reading : [Announcement] Ceremonial Turnover of HTA Implementation from the Department of Health to the Department of Science and Technology
[Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of Dapagliflozin for Patients with Type 2 Diabetes Mellitus
As of 07 March 2023, the Health Technology Assessment Council (HTA Council) has completed the assessment and deliberation for the preliminary recommendation on dapagliflozin 10 mg single-dose film-coated tablets as add-on treatment for adults with Type 2 Diabetes Mellitus including those who have or are at high risk of cardiovascular disease and/or diabetic neuropathy. The continue reading : [Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of Dapagliflozin for Patients with Type 2 Diabetes Mellitus